~~<i id='0733065ED3'><strike id='0733065ED3'><tt id='0733065ED3'><pre id='0733065ED3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：leisure time 2025-09-30 00:09:58 - browse：42

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

focus

knowledge

focus

explore

Wikipedia

SeanGallup/GettyImagesGutChecklooksathealthclaimsmadebystudies,newsmakers,orconventionalwisdom.Weask

WSS

Juul documents reveal insider tactics on political lobbying

Latigo launches with $135 million for Vertex

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Study: People of West African ancestry at greater risk of cardiac amyloidosis

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

hotspot

Wikipedia

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Elevance, private equity launch primary care company

Heart attack and stroke risk calculators need revising

Here’s what’s in the FDA plan to include pregnant women in clinical trials

The high cost of giving birth even with insurance

Having children helps parents live longer, especially after age 80

Activists slam private health insurers over coverage restrictions

Sanofi strikes deal with Novavax, boosting the vaccine maker

Sports medicine is finally prioritizing gender equality

Abbott's new heart device gets FDA advisory panel nod

knowledge

Making AI in medicine accessible to smaller, and rural hospitals

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Elevance, private equity launch primary care company

Eli Lilly reports tirzepatide MASH success during Q4 earnings

knowledge

focus

explore

Wikipedia